Processa Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
PCSA$1.95+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Expenses | ||
| Research and development expenses | $7,269,146 | $5,799,518 |
| General and administrative expenses | 4,782,060 | 5,657,543 |
| Operating Loss | (12,051,206) | (11,457,061) |
| Other Income (Expense) | ||
| Interest income, net | 201,088 | 335,541 |
| Net Operating Loss Before Income Tax Benefit | (11,850,118) | (11,121,520) |
| Income Tax Benefit | - | |
| Net Loss | $(11,850,118) | $(11,121,520) |
| Net Loss Per Common Share - Basic and Diluted | $(3.87) | $(8.48) |
| Weighted Average Common Shares Used to Compute | ||
| Net Loss Per Common Shares - Basic and Diluted | 3,059,906 | 1,311,572 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.